| Literature DB >> 35387281 |
Chunlei Zhang1, Yindong Kang1, Feiyan Kong2, Qi Yang1, Dehui Chang1.
Abstract
Background and purpose: Circular RNAs (circRNAs) are a big group of members of the noncoding RNA family following long non-coding RNA and microRNA. They play a regulatory role in many biological processes. Analyzing their current research status and future development trends is conducive to a more comprehensive understanding of circRNAs and contributes to the dedication to the biological field.Entities:
Keywords: Bibliometric analysis; Biblioshiny; CDR1as, antisense to the cerebellar degeneration-related protein 1 transcript; FOXO3, forkhead box O3; HIPK3, homeodomain interacting protein kinase 3; ITCH, itchy E3 ubiquitin protein ligase; MTO1, mitochondrial tRNA translation optimization 1; SMARCA5, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5; USA, The United States of America; ZNF609, zinc finger protein 609; circRNA; circRNA, circular RNA
Year: 2022 PMID: 35387281 PMCID: PMC8956961 DOI: 10.1016/j.ncrna.2022.03.001
Source DB: PubMed Journal: Noncoding RNA Res ISSN: 2468-0540
Main information about data of all articles and H-cited articles related to circRNA.
| Main information about data | ||
|---|---|---|
| Description | Total articles | H-cited articles |
| Timespan | 2000:2021 | 2011:2021 |
| Sources (Journals, Books, etc) | 650 | 83 |
| Documents | 3186 | 193 |
| Average years from publication | 1.79 | 3.66 |
| Average citations per documents | 31.43 | 271.5 |
| Average citations per year per doc | 7.583 | 49.2 |
| DOCUMENT CONTENTS | ||
| Keywords Plus (ID) | 3,534 | 487 |
| Author's Keywords (DE) | 5,740 | 392 |
| AUTHORS | ||
| Authors | 6,247 | 1,154 |
| Author Appearances | 21,870 | 1,774 |
| Authors of single-authored documents | 21 | 1 |
| Authors of multi-authored documents | 6,226 | 1,153 |
| AUTHORS COLLABORATION | ||
| Single-authored documents | 22 | 1 |
| Documents per Author | 0.51 | 0.167 |
| Authors per Document | 1.96 | 5.98 |
| Co-Authors per Documents | 6.86 | 9.19 |
| Collaboration Index | 1.97 | 6.01 |
Fig. 1Annual publication and citation of articles related to circRNA. A) annual scientific production of total published articles; B) annual scientific production of H-cited published articles; C) average article citations per year of total published articles; D) average article citations per year of H-cited published articles.
Fig. 2Relevant information of published articles related to circRNA. A) top 20 most relevant sources of total published articles; B) top 20 most relevant sources of H-cited published articles; C) top 20 most relevant authors of total published articles; D) top 20 most relevant authors of H-cited published articles; E) top 20 most relevant affiliations of total published articles; F) top 20 most relevant affiliations of H-cited published articles; G) top 10 most relevant key words of total published articles; E) top 10 most relevant key words of H-cited published articles.
Fig. 3Citation of H-cited published articles related to circRNA. A) top 20 most local cited documents; B) top 20 most local cited authors; C) top 20 most local cited sources; D) 14 most cited countries (average citations per year).
Fig. 4Co-occurrence network for the keywords in the H-cited literature. Cluster 1 was biological characteristics of circRNA (green part), cluster 2 was biological function of circRNA (blue part), cluster 3 was application of circRNA as a biomarker (red part). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 5Theme changes and trend of published articles related to circRNA from 2000 to 2021. A) thematic evolution of total published articles; B) thematic evolution of H-cited published articles; C) thematic map of total published articles; D) thematic map of H-cited published articles; E) trend topics of total published articles; F) trend topics of H-cited published articles.
Fig. 6Cooperative relationship of published articles. A) authors cooperative relationship in total published articles; B) authors cooperative relationship in H-cited published articles; C) affiliations cooperative relationship in total published articles; D) affiliations cooperative relationship in H-cited published articles; E) countries cooperative relationship in total published articles; F) countries cooperative relationship in H-cited published articles.
Top 20 authors with collaboration.
| Authors with collaboration | |||||
|---|---|---|---|---|---|
| Total articles | H-cited articles | ||||
| Node | Cluster | Betweenness | Node | Cluster | Betweenness |
| Li Y | 1 | 36.8 | Li J | 8 | 438.3 |
| Li X | 2 | 34.6 | Wang H | 7 | 270.4 |
| Wang Y | 1 | 33.0 | Wang Z | 7 | 237.0 |
| Zhang Y | 2 | 32.7 | Li Z | 4 | 225.4 |
| Li J | 3 | 27.7 | Sun W | 8 | 205.4 |
| Wang J | 4 | 25.1 | Zheng Q | 3 | 175.0 |
| Zhang X | 2 | 24.8 | Li X | 1 | 155.4 |
| Wang X | 3 | 18.0 | Wang X | 8 | 132.6 |
| Wang H | 4 | 17.3 | Chen Y | 6 | 91.0 |
| Liu Y | 2 | 16.3 | Zhang Y | 1 | 86.2 |
| Zhang J | 3 | 15.7 | Li T | 2 | 70.0 |
| Li H | 3 | 11.5 | Xiao B | 2 | 70.0 |
| Zhang L | 3 | 10.7 | Cui Y | 7 | 46.4 |
| Wang Z | 2 | 9.8 | Li P | 2 | 39.0 |
| Li Z | 3 | 7.1 | Li Y | 3 | 39.0 |
| Wang S | 4 | 6.9 | Zhou J | 8 | 39.0 |
| Liu X | 3 | 6.6 | Wang Y | 7 | 37.6 |
| Wang L | 1 | 5.7 | Xu Y | 7 | 24.4 |
| Liu J | 3 | 5.2 | Zhou Y | 7 | 23.4 |
| Chen J | 4 | 5.1 | Liu H | 4 | 2.6 |
Top 20 affiliations with collaboration.
| affiliation with collaboration | |||||
|---|---|---|---|---|---|
| Total articles | H-cited articles | ||||
| Fudan Univ | 1 | 367.3 | Shanghai Jiao Tong Univ | 1 | 17 |
| Nanjing Med Univ | 2 | 264.2 | Fudan Univ | 1 | 16 |
| Shanghai Jiao Tong Univ | 1 | 164.5 | Nanjing Med Univ | 3 | 13 |
| Peking Univ | 5 | 118.7 | Univ Chinese Acad Sci | 4 | 7 |
| Southern Med Univ | 3 | 117.1 | Sun Yat Sen Univ | 2 | 3 |
| Fujian Med Univ | 4 | 89.7 | Tongji Univ | 1 | 0 |
| Guangzhou Med Univ | 3 | 87.2 | Tianjin Med Univ | 1 | 0 |
| Tongji Univ | 1 | 78.5 | Southern Med Univ | 2 | 0 |
| Capital Med Univ | 5 | 78.0 | Guangzhou Med Univ | 2 | 0 |
| Shandong Univ | 1 | 66.9 | Guangzhou Univ Chinese Med | 2 | 0 |
| Sun Yat Sen Univ | 3 | 62.8 | Southeast Univ | 3 | 0 |
| Xiamen Univ | 4 | 45.0 | Nanjing Univ | 3 | 0 |
| Harbin Med Univ | 3 | 45.0 | Shanghaitech Univ | 4 | 0 |
| Second Mil Med Univ | 1 | 26.6 | Univ Toronto | 5 | 0 |
| Chongqing Med Univ | 6 | 21.8 | Sunnybrook Res Inst | 5 | 0 |
| Huazhong Univ Sci And Technol | 4 | 19.1 | |||
| Nanchang Univ | 3 | 18.8 | |||
| Peking Union Med Coll | 5 | 14.3 | |||
| Xuzhou Med Univ | 2 | 11.6 | |||
| Kunming Med Univ | 6 | 8.0 | |||
Top 20 countries with the most published articles.
| Countries with the most published articles | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total articles | H-cited articles | ||||||||
| China | 2735 | 2542 | 193 | 0.07 | China | 144 | 124 | 20 | 0.14 |
| USA | 129 | 90 | 39 | 0.30 | USA | 19 | 14 | 5 | 0.26 |
| Germany | 54 | 35 | 19 | 0.35 | Germany | 12 | 6 | 6 | 0.50 |
| Canada | 24 | 6 | 18 | 0.75 | Canada | 4 | 1 | 3 | 0.75 |
| Spain | 24 | 16 | 8 | 0.33 | Italy | 3 | 1 | 2 | 0.67 |
| Italy | 22 | 10 | 12 | 0.55 | Denmark | 2 | 1 | 1 | 0.50 |
| Japan | 21 | 20 | 1 | 0.05 | Israel | 2 | 2 | 0 | 0 |
| Denmark | 19 | 13 | 6 | 0.32 | Austria | 1 | 1 | 0 | 0 |
| India | 18 | 15 | 3 | 0.17 | France | 1 | 0 | 1 | 1 |
| Australia | 15 | 8 | 7 | 0.47 | India | 1 | 1 | 0 | 0 |
| France | 15 | 6 | 9 | 0.60 | Japan | 1 | 1 | 0 | 0 |
| Iran | 14 | 11 | 3 | 0.21 | Netherlands | 1 | 0 | 1 | 1 |
| Netherlands | 11 | 6 | 5 | 0.45 | Singapore | 1 | 1 | 0 | 0 |
| Malaysia | 9 | 4 | 5 | 0.56 | Spain | 1 | 0 | 1 | 1 |
| Russia | 8 | 8 | 0 | 0.00 | |||||
| Korea | 7 | 7 | 0 | 0.00 | |||||
| Switzerland | 7 | 2 | 5 | 0.71 | |||||
| United kingdom | 7 | 3 | 4 | 0.57 | |||||
| Austria | 5 | 2 | 3 | 0.60 | |||||
| Brazil | 5 | 5 | 0 | 0.00 | |||||
Tips: SCP: single country publications, MCP: multiple country publications.
Fig. 7Countries with the highest number of published articles related to circRNA. A) total published articles; B) H-cited articles.
Top 20 countries with collaboration.
| countries with collaboration | |||||
|---|---|---|---|---|---|
| Total articles | H-cited articles | ||||
| China | 1 | 116.0 | Germany | 2 | 30.5 |
| USA | 1 | 97.6 | USA | 1 | 18.6 |
| Germany | 3 | 74.1 | China | 1 | 9.5 |
| Denmark | 3 | 32.3 | Australia | 2 | 0.4 |
| Australia | 2 | 27.9 | Canada | 1 | 0 |
| Netherlands | 3 | 3.5 | Japan | 1 | 0 |
| France | 3 | 3.1 | Italy | 2 | 0 |
| United kingdom | 3 | 0.8 | Israel | 2 | 0 |
| Italy | 3 | 0.4 | Argentina | 2 | 0 |
| Canada | 1 | 0.2 | Sweden | 2 | 0 |
| Spain | 3 | 0.1 | United kingdom | 2 | 0 |
| India | 1 | 0 | |||
| Malaysia | 1 | 0 | |||
| Poland | 1 | 0 | |||
| Pakistan | 1 | 0 | |||
| New zealand | 1 | 0 | |||
| Sudan | 1 | 0 | |||
| Japan | 2 | 0 | |||
| Iran | 2 | 0 | |||
| Singapore | 2 | 0 | |||
Top 20 world countries collaboration.
| world country collaboration | |||||
|---|---|---|---|---|---|
| Total articles | H-cited articles | ||||
| China | USA | 152 | China | USA | 20 |
| China | Canada | 33 | USA | Germany | 5 |
| China | Australia | 17 | China | Canada | 3 |
| USA | Germany | 16 | Germany | Israel | 3 |
| China | Germany | 11 | China | Australia | 2 |
| China | United kingdom | 10 | China | Japan | 2 |
| USA | Denmark | 10 | Germany | Argentina | 2 |
| USA | Italy | 9 | Germany | Australia | 2 |
| Germany | United kingdom | 8 | Germany | Italy | 2 |
| China | Japan | 7 | Germany | Sweden | 2 |
| Germany | Australia | 7 | Germany | United kingdom | 2 |
| China | Pakistan | 6 | USA | Australia | 2 |
| Germany | Netherlands | 6 | USA | Italy | 2 |
| USA | India | 6 | USA | Japan | 2 |
| Canada | Pakistan | 5 | Argentina | Korea | 1 |
| Germany | France | 5 | Argentina | Sweden | 1 |
| Germany | Italy | 5 | Argentina | United kingdom | 1 |
| USA | Australia | 5 | Australia | Argentina | 1 |
| USA | Canada | 5 | Australia | Denmark | 1 |
| China | Denmark | 4 | Australia | France | 1 |
Articles of circRNAs that have been mainly investigated.
| First author, year | circRNA | host gene | title | topic | Ref. |
|---|---|---|---|---|---|
| Memczak S, 2013 | CDR1as | CDR1 | Circular RNAs are a large class of animal RNAs with regulatory potency | miRNA sponge | [ |
| Guo J, 2014 | CDR1as | CDR1 | Expanded identification and characterization of mammalian circular RNAs | properties of circRNAs | [ |
| Piwecka M, 2017 | CDR1as | CDR1 | Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function | brain function | [ |
| Xu H, 2015 | CDR1as | CDR1 | The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells | insulin transcription and secretion | [ |
| Kleaveland B, 2018 | CDR1as | CDR1 | A network of noncoding regulatory RNAs acts in the mammalian brain | mammalian brain | [ |
| Du W, 2016 | circFOXO3 | FOXO3 | Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2 | cell cycle | [ |
| Du W, 2017 | circFOXO3 | FOXO3 | Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses | cardiac senescence | [ |
| Du W, 2017 | circFOXO3 | FOXO3 | Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity | tumor apoptosis | [ |
| Shen Z, 2020 | circFOXO3 | FOXO3 | Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel | prostate cancer | [ |
| Kong Z, 2020 | circFOXO3 | FOXO3 | Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p | prostate cancer | [ |
| Zheng Q, 2016 | circHIPK3 | Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs | cell growth | [ | |
| Li Y, 2017 | circHIPK3 | HIPK3 | CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells | bladder cancer | [ |
| Zeng K, 2018 | circHIPK3 | HIPK3 | CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7 | colorectal cancer | [ |
| Shan K, 2017 | circHIPK3 | HIPK3 | Circular noncoding RNA HIPK3 mediatesretinalvascular dysfunction in diabetes mellitus | diabetes mellitus | [ |
| Chen G, 2018 | circHIPK3 | HIPK3 | circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma | hepatocellular carcinoma | [ |
| Yang C, 2018 | circITCH | HIPK3 | Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression | bladder cancer | [ |
| Guo W, 2017 | circITCH | ITCH | Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma | hepatocellular carcinoma | [ |
| Wang M, 2018 | circITCH | ITCH | CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22–3p/CBL/beta-catenin pathway | thyroid cancer | [ |
| Wang S, 2019 | circITCH | ITCH | Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/beta-catenin pathway | breast cancer | [ |
| Hu J, 2018 | circITCH | ITCH | The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling | ovarian carcinoma | [ |
| Han D, 2017 | circMTO1 | MTO1 | Circular RNA circMTO1 Acts as the Sponge of MicroRNA-9 to Suppress Hepatocellular Carcinoma Progression | hepatocellular carcinoma | [ |
| Li Y, 2019 | circMTO1 | MTO1 | Circular RNA circMTO1 suppresses bladder cancer metastasis by sponging miR-221 and inhibiting epithelial-to-mesenchymal transition | bladder cancer | [ |
| Ge Z, 2018 | circMTO1 | MTO1 | CircMTO1 inhibits cell proliferation and invasion by regulating Wnt/beta-catenin signaling pathway in colorectal cancer | colorectal cancer | [ |
| Chen M, 2019 | circMTO1 | MTO1 | circMTO1 promotes tumorigenesis and chemoresistance of cervical cancer via regulating miR-6893 | cervical cancer | [ |
| Zhang B, 2019 | circMTO1 | MTO1 | A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma | lung adenocarcinoma | [ |
| Tan Y, 2019 | circSMARCA5 | SMARCA5 | Circular RNA SMARCA5 is overexpressed and promotes cell proliferation, migration as well as invasion while inhibits cell apoptosis in bladder cancer | bladder cancer | [ |
| Kong Z, 2017 | circSMARCA5 | SMARCA5 | Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer | prostate cancer | [ |
| Tong S, 2020 | circSMARCA5 | SMARCA5 | Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer | non-small cell lung cancer | [ |
| Liu H, 2019 | circSMARCA5 | SMARCA5 | Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767–5p | multiple myeloma | [ |
| Miao X, 2020 | circSMARCA5 | SMARCA5 | Circ-SMARCA5 suppresses colorectal cancer progression via downregulating miR-39–3p and upregulating ARID4B | colorectal cancer | [ |
| Zuo Y, 2020 | circZNF609 | ZNF609 | Circular RNA Circ-ZNF609 Promotes Lung Adenocarcinoma Proliferation by Modulating miR-1224–3p/ETV1 Signaling | lung adenocarcinoma | [ |
| Guan C, 2021 | circZNF609 | ZNF609 | YY1 and eIF4A4 are mediators of the cell proliferation, migration and invasion in cholangiocarcinoma promoted by circ-ZNF609 by targeting miR-432–5p to regulate LRRC1 | cholangiocarcinoma | [ |
| Du S, 2021 | circZNF609 | ZNF609 | Circular RNA ZNF609 promotes the malignant progression of glioma by regulating miR-1224–3p/PLK1 signaling | glioma | [ |
| Wu L, 2018 | circZNF609 | ZNF609 | Circ-ZNF609 promotes migration of colorectal cancer by inhibiting Gli1 expression via microRNA-150 | colorectal cancer | [ |
| Liu Z, 2019 | circZNF609 | ZNF609 | Circ-ZNF609 promotes carcinogenesis of gastric cancer cells by inhibiting miRNA-145–5p expression | gastric cancer | [ |